MYUNGMOON Pharm co.,Ltd

A017180

KR7017180001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
2,070 ^KRW	+1.47%		-0.24%	-9.41%

Mar. 20	MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Tranche Update on MYUNGMOON Pharm co.,Ltd's Equity Buyback Plan announced on May 25, 2023.	CI

Tranche Update on MYUNGMOON Pharm co.,Ltd's Equity Buyback Plan announced on May 25, 2023.

November 27, 2023 at 01:52 am EST

From October 1, 2023 to November 25, 2023, the company has repurchased 0 shares, representing 0% for KRW 0 million. With this, the company has completed the repurchase of 278,592 shares, representing 0.82% for KRW 674.93 million under the buyback announced on May 25, 2023.

Latest news about MYUNGMOON Pharm co.,Ltd

MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Tranche Update on MYUNGMOON Pharm co.,Ltd's Equity Buyback Plan announced on May 25, 2023.	Nov. 27	CI
Tranche Update on MYUNGMOON Pharm co.,Ltd's Equity Buyback Plan announced on May 25, 2023.	Nov. 27	CI
MYUNGMOON Pharm co.,Ltd's Equity Buyback announced on May 25, 2023, has expired with 278,592 shares, representing 0.82% for KRW 674.93 million.	Nov. 24	CI
MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Tranche Update on MYUNGMOON Pharm co.,Ltd's Equity Buyback Plan announced on May 25, 2023.	23-08-28	CI
MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
MYUNGMOON Pharm co.,Ltd announces an Equity Buyback for KRW 1,000 million worth of its shares.	23-05-24	CI
MYUNGMOON Pharm co.,Ltd authorizes a Buyback Plan.	23-05-24	CI
MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-14	CI
MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-13	CI
MYUNGMOON Pharm co.,Ltd(KOSE:A017180) dropped from S&P Global BMI Index	22-09-19	CI
MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-15	CI
MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-14	CI
M2N Co.,Ltd cancelled the acquisition of an unknow stake in MYUNGMOON Pharm co.,Ltd.	21-11-11	CI
M2N Co.,Ltd agreed to acquire an unknow stake in MYUNGMOON Pharm co.,Ltd.	21-11-03	CI
Woo Seok-min agreed to acquire 2.4% stake in Myungmoon Investment Development Co. Ltd. from MYUNGMOON Pharm co.,Ltd for KRW 2.1 billion.	21-06-24	CI
Myungmoon Pharm. Co., LTD.(KOSE:A017180) added to S&P Global BMI Index	20-09-21	CI
Myungmoon Pharm. Co., LTD.(KOSE:A017180) dropped from S&P Global BMI Index	19-09-23	CI
Myungmoon Pharm. Co., LTD. announced that it has received KRW 15 billion in funding from a group of investors	19-01-28	CI
Myungmoon Pharm. Co., LTD. announced that it expects to receive KRW 15 billion in funding from a group of investors	19-01-24	CI
Myungmoon Pharm. Co., LTD.(KOSE:A017180) added to S&P Global BMI Index	18-09-24	CI
Jong-min Kim acquired 0.93% stake in Myungmoon Pharm. Co., LTD. from Woo, Seok-Min for approximately KRW 300 million.	14-01-09	CI

Chart MYUNGMOON Pharm co.,Ltd

Duration

Period

More charts

Company Profile

MyungMoon Pharm. Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. Its products include ethical (ETC) drugs and over the counter (OTC) drugs. Its ETC drugs include anesthetic agents, digestive system drugs, rheumatoid arthritis remedies, central nervous system drugs, circulatory drugs, anti-depressant agents, anti-diabetic agents, antibiotics, hormone agents, narcotics and drugs for dermatology systems. Its OTC drugs include antinauseant agents, hepatic agents, immunologic agents, antidiarrheal agents, skin external preparations, antiallergic agents, muscle relaxants, cold drugs and parasiticides. The Company is also involved in the operation golf courses. January 2, 2012, the Company completed the merger with its wholly owned subsidiary.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MYUNGMOON PHARM CO.,LTD	-9.41%	50.43M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B